Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Hematologic Neoplasms 1COVID-19 1

Interventions

Standard of Care 2tocilizumab 1selinexor 1lenzilumab 1cilgavimab and tixagevimab drug combination 1Practice Guidelines as Topic 1Observation 1Interferon-alpha 1Immunoglobulin G 1IMM-101 1Disulfides 1CVnCoV COVID-19 vaccine 1COVID-19 Vaccines 1BNT162 Vaccine 1Atorvastatin 12019-nCoV Vaccine mRNA-1273 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × COVID-19 × cilgavimab and tixagevimab drug combination × Clear all
NCT05438498 2023-09-08

Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2

MediMergent, LLC

Phase 3 Terminated
550 enrolled
Other hematologic neoplasm

COVID-19, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡